Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics, and Explore Efficacy of TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis
Conditions
Interventions
TEPEZZA
Placebo
Locations
7
United States
UCLA Division of Rheumatology
Los Angeles, California, United States
Pacific Arthritis Care Center
Los Angeles, California, United States
Yale North Haven Medical Center
New Haven, Connecticut, United States
The Johns Hopkins Bayview Medical Center
Baltimore, Maryland, United States
The Cleveland Clinic
Cleveland, Ohio, United States
University of Toledo Medical Center
Toledo, Ohio, United States
Start Date
November 17, 2021
Primary Completion Date
November 29, 2022
Completion Date
December 8, 2022
Last Updated
June 28, 2024
NCT05270668
NCT04986605
NCT03198689
NCT02161406
NCT00433186
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions